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Abstract: Anterior mediastinal masses are relatively uncommon, 
include a wide variety of entities, and often pose a diagnostic chal-
lenge for clinicians. In this article, available data is assembled in a 
clinically oriented manner to develop a structured approach to evalu-
ation of these patients. Attention to age and gender, combined with 
identification of certain radiographic and clinical characteristics, 
allows a presumptive diagnosis to be established in most patients. 
This structure efficiently guides what additional workup is needed.
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Mediastinal masses are relatively uncommon. Most occur in the anterior compartment and include a variety of 
different entities demonstrating a spectrum of clinical and 
pathologic features. A simple, uniform “standard” approach 
to these patients is not appropriate given the heterogeneity and 
variety of different features that can be characteristic of partic-
ular entities. Whether to pursue specific laboratory tests, look 
for specific associated conditions, obtain additional imaging 
or biopsy depends on which entities are realistic possibilities.
Particularly because most clinicians encounter such 
patients only occasionally, there is a need for some structure 
in how to proceed with evaluating them. Unfortunately, most 
reports do not provide information that lends itself to clinical 
application; these series start with a specific known diagnosis 
and describe the cohort, whereas the clinician is faced with a 
patient with certain characteristics (such as age and appear-
ance of the lesion) and is struggling to arrive at a diagnosis.
A structured, clinically oriented approach increases 
the efficiency of the investigation and eliminates unneces-
sary studies. In this article, we review key features of ante-
rior mediastinal lesions and propose a clinical approach to the 
evaluation of these masses. The approach taken is to begin 
with features that are readily available (e.g., age, sex) and then 
to consider aspects of the clinical presentation to develop an 
initial presumptive diagnosis. The lesion under consideration 
and the degree of certainty about the presumptive diagno-
sis guide the next steps in an efficient manner. Some tumors 
are immediately and reliably recognizable; however, because 
these are more rare entities, in general it is best to focus first on 
the more common entities and to consider uncommon lesions 
primarily when the common ones have been deemed unlikely. 
This review is intended to serve as a general structure to the 
approach that we hope can guide management; it is important 
to note that these are general statements and that there will 
always be exceptions.
METHODS
A core workgroup (F.C.D., E.M.M., and B.W.C.) 
reviewed the existing literature on the evaluation of patients 
presenting with an anterior mediastinal mass. This group 
drafted the proposed approach to the patient presenting with 
an anterior mediastinal mass. The document was then reviewed 
by an extended workgroup (Motoki Yano, Ricardo Beyruti, In 
Kyu Park, Alper Toker, Marinus A. Paul, Ehab Bishay, and 
Stephen D. Cassivi).
In the generation of this review, series from 1950 to 
2010 that included age- and gender-specific data on the 
incidence of mediastinal tumors were analyzed.1 Additional 
studies that reviewed data on the relative proportions of medi-
astinal tumors were also included. Some older series were 
excluded which included lesions that could not be accurately 
translated into modern classification schemes and diagnostic 
categories. The data regarding the incidence of anterior medi-
astinal masses is an approximation and does not represent a 
precise quantitative incidence.
NOMENCLATURE
Although the nomenclature that is typically used for 
classification of anterior mediastinal masses is fairly straight-
forward, several specific entities and circumstances necessitate 
discussion. For instance, although thymic malignancies such 
as thymic carcinoma and thymic carcinoid are distinct and 
separate entities from thymoma, these tumors were included 
under the term “thymoma” in some series. In order to be con-
sistent, we have considered these entities as one group (thymic 
malignancy) in this article. Numerous classification schemes 
have been devised for lymphomas. As many series included 
in this review employed the Revised European-American 
Lymphoma system, this scheme is used in this article. The 
most common lymphomas resulting in anterior mediastinal 
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masses include Hodgkin disease (HD), mediastinal large cell 
(MLC) non-Hodgkin lymphoma (NHL), and lymphoblastic 
(LB)-NHL.
The term teratoma in this article refers to benign pri-
mary mediastinal teratomas, which may also be referred to 
as mature teratomas or dermoid cysts. We did not follow 
the policy of some series which included such benign tera-
tomas in the category of germ cell tumors along with pri-
mary mediastinal seminoma and non-seminomatous tumors 
(NSGCTs). Furthermore, the term teratoma in this review 
does not encompass secondary mediastinal teratomas, 
which represent residual neoplasms following treatment of 
NSGCTs with chemotherapy, or malignant teratomas that 
appear secondarily in this setting as well. Such secondary 
tumors are excluded entirely from this article, because they 
are not part of the differential diagnosis of primary anterior 
mediastinal tumors.
The data presented in this review is based on papers that 
have defined the anterior mediastinal compartment according 
to various schemes (based on the lateral chest radiograph). 
Nevertheless, the approach outlined here is applicable to the 
more well-defined computed tomography (CT)-based defini-
tion of anterior mediastinal compartment described elsewhere 
in this issue.2
INCIDENCE
The true incidence of anterior mediastinal masses is 
difficult to ascertain from the medical literature for several 
reasons. For one, different clinical and/or radiologic classifi-
cation schemes may be used to define mediastinal compart-
ments. Additionally, the inclusion of nonneoplastic lesions 
such as thymic and pericardial cysts is variable between dif-
ferent series. Finally, there is variability in the inclusion of 
lymphomas in different series. Whereas 50% of HD and 20% 
of NHL involve the mediastinum,3 only approximately 3% of 
HD and 6% of NHL arise as primary mediastinal malignan-
cies.4–6 Inclusion of the latter group as mediastinal tumors is 
warranted because they are located primarily in the mediasti-
num and are clearly a consideration in a patient with an ante-
rior mediastinal mass. However, inclusion of lymphomas that 
present as obvious extrathoracic tumors seems inappropriate; 
pathologically enlarged extrathoracic lymph nodes (e.g., neck, 
groin, or axilla) can be easily sampled by percutaneous biopsy 
and these patients are not viewed as presenting with an ante-
rior mediastinal mass.1
Despite these challenges in determining an exact 
incidence, several studies have demonstrated that the most 
common anterior mediastinal masses include the following 
entities: thymic malignancy in approximately 35%, lymphoma 
in approximately 25% (HD, 13% and NHL, 12%), thyroid and 
other endocrine tumors in approximately 15%, benign tera-
toma in approximately 10%, malignant germ cell tumors in 
approximately 10% (seminoma, 4% and NSGCT, 7%), and 
benign thymic lesions in approximately 5%.7–9
CLINICAL APPROACH TO AN ANTERIOR 
MEDIASTINAL MASS
This review article approaches evaluation of an anterior 
mediastinal mass from a clinical perspective, which typically 
begins with a detailed patient history and focused physical 
examination. Age and gender are the two most important initial 
features to consider in the evaluation of patients with an ante-
rior mediastinal mass, as specific lesions tend to be more com-
mon in certain demographic groups (Table 1). The presence of 
particular clinical symptoms, the severity and duration of these 
symptoms, and the presence of additional signs and symptoms 
can provide important clues to the diagnosis. Additional tests 
such as laboratory studies, the most common of which include 
α-fetoprotein (α-FP), β-human chorionic gonadotropin (β-
HCG), and lactate dehydrogenase (LDH), play an important 
adjunctive role. Features of anterior mediastinal masses in 
imaging studies can sometimes be essentially pathognomonic, 
but are more often only suggestive of a particular diagnosis by 
themselves; details are discussed in Approaching the Patient 
with an Anterior Mediastinal Mass: A Guide for Radiologists.10 
CT is the recommended imaging modality for the evalua-
tion of most anterior mediastinal masses. However, magnetic 
resonance imaging (MRI) is superior to CT in distinguishing 
cystic from solid masses, can be performed without contrast 
in patients who cannot receive intravenous contrast as part of 
a CT examination (due to renal failure or allergy), and can 
be used to differentiate thymic hyperplasia from thymoma 
through the use of chemical shift techniques. 18F-FDG PET/
CT is not routinely performed to evaluate or characterize an 
anterior mediastinal mass, but is typically used to stage lym-
phomas and monitor response to therapy. In most patients, a 
combination of demographic information, clinical presenta-
tion, and imaging features allows a presumptive diagnosis to 
be made with a fair amount of confidence.
Women And Men Older Than 40 Years
The proportion of anterior mediastinal lesions by decade 
in women and men greater than 40 years of age is demonstrated 
in Figure 1. In this patient population, thyroid goiter and thy-
mic malignancies account for more than two-thirds of anterior 
mediastinal masses. Most substernal thyroid goiters manifest 
as a hyperdense mediastinal mass in continuity with the thy-
roid gland and extending posterior to the great vessels on CT.11
The majority of anterior mediastinal lesions in the 
remainder of patients in this group represent thymic malig-
nancy. Clinical evaluation of these patients is paramount, as 
approximately 30% to 50% of patients with thymoma will 
exhibit paraneoplastic syndromes. The most common para-
neoplastic syndrome associated with thymoma is myasthe-
nia gravis, followed by hypogammaglobulinemia and pure 
red cell aplasia.12,13 Autoimmune disorders such as systemic 
lupus erythematosis, polymyositis, and myocarditis may 
also be associated with thymoma.14 CT is typically the ini-
tial imaging modality used to evaluate for thymoma, and a 
homogeneous or slightly heterogeneous soft tissue mass in 
the anterior mediastinum with smooth or lobular margins is 
the usual finding. However, when paraneoplastic syndromes 
are present, such as myasthenia gravis, an increasing number 
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TABLE 1.  Clinical Approach to Adult Patients with an Anterior Mediastinal Mass
α-FP, serum α-fetoprotein; β-HCG, β-human chorionic gonadotropin; “B” symptoms, fever, night sweats, anorexia; ↑, increased; HD, Hodgkin disease; LB-
NHL, lymphoblastic non-Hodgkin lymphoma; LDH, lactate dehydrogenase; MG, myasthenia gravis; MLC-NHL, mediastinal large cell non-Hodgkin lymphoma; 
NSGCT, non-seminomatous germ cell tumor.
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of clinicians are ordering MRI as the initial examination 
for investigation. MRI has the advantage of differentiating 
thymic hyperplasia and thymoma with greater accuracy and 
lacks ionizing radiation.
In patients of this age group, especially women and 
individuals older than 50 years of age, a clinical diagnosis of 
substernal goiter or thymoma can be made reliably, and tis-
sue confirmation is typically not necessary prior to surgical 
resection. However, there is a small subset of patients, typi-
cally men and individuals 40 to 49 years of age, who present 
with anterior mediastinal lesions that are not recognizable as 
goiter or thymoma. Such masses are most likely to represent 
relatively rare tumors such as benign teratoma, seminoma, 
and NSGCT, as well as benign lesions such as thymic cysts. 
The imaging appearance of teratoma is typically sufficient to 
reliably make the diagnosis; however, other entities may need 
further evaluation with more advanced imaging or biopsy. For 
instance, when a well-circumscribed, round/oval/saccular, 
and homogeneous lesion near the thymic bed is present on 
CT, consideration should be given to thymic cyst and further 
evaluation with MRI performed. For masses requiring tissue 
diagnosis, although initial evaluation with needle biopsy is 
desirable, surgical biopsy may ultimately be necessary given 
the wide variety and relatively rarity of these tumors. If an 
NSGCT is specifically suspected, serum α-FP and β-HCG 
levels can be diagnostic, but in general these tests are rarely 
indicated in men over age 40 with an anterior mediastinal 
mass.
Women 10 To 39 Years Of Age
The proportion of anterior mediastinal lesions by 
decade in women 10 to 39 years of age is demonstrated in 
FIGURE 1.  Anterior mediastinal tumors in patients over age 40 years. Proportion of tumor types by decades of age: (A) 
Women, (B) Men. Modified from Detterbeck F. Clinical Approach to Mediastinal Masses.1 HD/MLC-NHL, Hodgkin’s disease/
mediastinal large cell non-Hodgkin’s lymphoma; LB-NHL, lymphoblastic non-Hodgkin’s lymphoma; NSGCT, non-seminomatous 
germ cell tumor.
FIGURE 2.  Anterior mediastinal tumors in patients age 10 to 39 years. Proportion of tumor types by decades of age: (A) 
Women, (B) Men. Modified from Detterbeck.1 HD/MLC-NHL, Hodgkin’s disease/mediastinal large cell non-Hodgkin’s lym-
phoma; LB-NHL, lymphoblastic non-Hodgkin’s lymphoma; NSGCT, non-seminomatous germ cell tumor.
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Figure 2. In this patient population, the most common anterior 
mediastinal tumor is lymphoma, specifically HD or MLC-
NHL. Clinical symptoms reported at the time of presentation 
include “B” symptoms such as fever, night sweats, and weight 
loss, and other symptoms typically associated with lym-
phoma. Enlarged lymph nodes in the cervical, supraclavicular, 
and axillary regions may be palpable on physical examination. 
on CT, the most common finding is a mediastinal mass or 
multiple enlarged lymph nodes which may or may not be seen 
in combination with enlarged lymph nodes elsewhere. FDG-
PET/CT has become the modality of choice for staging most 
lymphomas and is more accurate at detecting both intranodal 
and extranodal disease than CT.15 In this patient population 
with the appropriate clinical symptoms or findings on physical 
examination, a presumptive diagnosis of HD or MLC-NHL 
may reliably be made. However, tissue is necessary to define 
the lymphoma subtype and for treatment planning. Although 
initial evaluation may be performed with needle biopsy, surgi-
cal biopsy may be necessary to obtain adequate tissue for full 
lymphoma characterization.1
After lymphoma, the next most common anterior medi-
astinal tumor in this group of patients is thymic malignancy, 
especially in patients over 20 years of age. A careful clinical 
examination to evaluate for a thymic paraneoplastic syndrome 
is recommended because often this will establish the diagno-
sis of thymoma essentially without a doubt.12,13
Benign teratoma is another relatively common ante-
rior mediastinal tumor in this patient population, especially 
in younger patients (<25 years old). Teratomas consist of 
two or more of the following tissue types: ectoderm (hair, 
skin, and teeth), mesoderm (bone, cartilage, and muscle), 
and endoderm (bronchial and gastrointestinal epithelium, 
mucus glands, and pancreatic glands). These lesions can 
be classified as mature (more common, consisting of well-
differentiated tissues) or immature. Most of these patients 
are asymptomatic.16,17 However, long-standing signs and 
symptoms such as chest pain (29%), cough (25%), dys-
pnea (22%), pleural effusion (9%), and superior vena cava 
syndrome (1%) may be present.18,19 Teratomas are rounded 
tumors that may be entirely cystic or contain varying 
amounts of fat, soft tissue, and calcification.19 The presence 
of fat or fat–fluid levels is highly suggestive of the diagnosis 
(present in ~50% of cases).19 Calcification is present in 25% 
of tumors, and structures such as bone or teeth are seen in 
less than 10%.16,18,20
Therefore, most anterior mediastinal lesions in women 
10 to 39 years of age represent lymphoma, thymoma, or benign 
teratoma, and a reliable presumptive diagnosis of these entities 
is typically easily made. Tissue confirmation may be performed 
prior to surgical resection, although this is usually not needed 
for thymomas and teratomas. In the remainder of these patients, 
a variety of lesions may be present. A small number of individ-
uals will have substernal goiter, which is easily diagnosed on 
CT. LB-NHL should be considered in patients 10 to 19 years of 
age, especially in the setting of rapid symptom onset. The most 
common finding on CT is a large heterogeneous mass that is 
often seen in association with a pleural effusion. Cytologic 
analysis is typically sufficient to make the diagnosis.1 If all 
these diagnoses are considered unlikely, assessing α-FP and β-
HCG may be beneficial, especially in women 20 to 29 years of 
age, because the possibility of NSGCT in this subset of tumors 
not lending themselves to a presumptive clinical diagnosis is 
greater (whereas it is seen in <5% of all women age 10–39 
years with an anterior mediastinal mass). In the remainder of 
patients a tissue biopsy is needed.
Men 10 To 39 Years Of Age
The proportion of anterior mediastinal lesions by decade 
in men 10 to 39 years of age is demonstrated in Figure 2. In 
this patient population, there is no dominant tumor type; an 
assessment of the rapidity of onset of symptoms is very help-
ful in narrowing the differential diagnosis (Table 2).
A rapid onset of symptoms, over the course of days 
to weeks, is strongly associated with NSGCT or LB-NHL, 
both of which manifest as large heterogeneous masses on 
CT.12,20 LB-NHL is more common in individuals 10 to 20 
years of age, and affected patients typically present with 
“B” symptoms, an elevated serum LDH level, and a pleural 
effusion. Diagnosis of LB-NHL may be made by fine needle 
aspiration of the primary mediastinal mass, bone marrow, 
or, when present, an associated pleural effusion, due to char-
acteristic features on cytology.1 Markedly elevated serum 
α-FP or β-HCG levels are present in 90% of patients with 
NSGCT and are pathognomonic.21–24 Although pulmonary 
metastases may be present, pleural effusions are uncommon. 
Many experienced centers consider a typical radiographic 
and clinical presentation and markedly elevated α-FP or β-
HCG levels to be sufficiently diagnostic to obviate the need 
for a biopsy.1
An intermediate onset of symptoms, over weeks to 
months, in this group suggests seminoma, HD, or MLC-
NHL. Approximately 10% of patients with seminoma 
demonstrate slightly elevated serum β-HCG, but α-FP 
is typically normal.20,23,25 Serum LDH levels are usually 
TABLE 2.  Clinical Algorithm for Anterior Mediastinal Tumors 
in Men Ages 10–39 Years
α-FP, serum α-fetoprotein; β-HCG, β-human chorionic gonadotropin; ↑, increased; 
Alk ϕ, serum alkaline phosphatase; FNAB, fine needle aspiration or core needle biopsy; 
HD/MLC, Hodgkin’s disease/mediastinal large cell lymphoma; LB-NHL, lymphoblastic 
non-Hodgkin’s lymphoma; LDH, lactate dehydrogenase; NSGCT, non-seminomatous 
germ cell tumor; WBC, white blood cell count.
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elevated.22,26 Although pleural effusions are rare, pulmonary 
metastases are relatively common. Core needle biopsy is 
typically sufficient to make the diagnosis of seminoma. HD 
and MLC-NHL manifest as multiple enlarged lymph nodes 
or lobulated masses in the mediastinum. Involvement of 
multiple nodal groups such as cervical, hilar, and abdominal 
groups is suggestive of HD. MLC-NHL is typically isolated 
to the mediastinum and may be associated with pleural or 
pericardial effusions. “B” symptoms are usually present in 
HD and MLC-NHL. A biopsy (needle or surgical) is neces-
sary to fully characterize the type of lymphoma, which deter-
mines the optimal treatment.1
Thymoma and benign teratomas are the most common 
anterior mediastinal tumors in asymptomatic patients and 
those with prolonged onset of symptoms. In this group, thy-
moma is more common in patients older than 30 years and 
teratoma is more common in patients younger than 20 years. 
The presence of paraneoplastic syndromes such as myas-
thenia gravis strongly suggests the diagnosis of thymoma, 
but may also be present in thymic hyperplasia. Thymic 
hyperplasia should be considered in patients with an ante-
rior mediastinal mass who have been treated with chemo-
therapy, radiation therapy, or corticosteroids, who have been 
exposed to stresses such as burns or injuries, or who have 
known disorders such as myasthenia gravis, hyperthyroid-
ism, collagen vascular diseases, or HIV. Thymic hyperpla-
sia should be considered when uniform enlargement of the 
thymus is present in a young patient. Thoracic MRI using 
chemical shift techniques is helpful in differentiating thy-
mic hyperplasia from thymomas and other anterior medias-
tinal tumors.27 All thymomas should be surgically resected 
if clinically feasible. Although teratomas are benign lesions, 
surgical resection may be performed when symptoms are 
present, especially in young patients. Thymic hyperplasia 
may be observed or treated with surgical resection in cases 
of significant myasthenia gravis.
Children 0 To 9 Years Of Age
The proportion of anterior mediastinal lesions in chil-
dren 0 to 9 years of age is demonstrated in Figure 3. In this 
patient population, there is no dominant tumor type, and 
symptoms at presentation are the key feature. A rapid onset 
of symptoms is suggestive of LB-NHL, an intermediate onset 
HD or MLC-NHL, and a chronic onset other tumors such as 
teratoma. Thymic lesions also occur, although most are benign 
(thymic cysts or hyperplasia). Specific clinical symptoms, lab-
oratory tests, and confirmatory procedures for these entities 
are the same in this age group as those previously discussed 
for older patients.
HISTOLOGIC SAMPLING AND BIOPSY 
CONSIDERATIONS
Because certain anterior mediastinal entities manifest 
highly characteristic clinical symptoms or findings, not all 
lesions in the anterior mediastinum are biopsied. For exam-
ple, most thyroid goiters result in pathognomonic findings 
on CT and are diagnosed by imaging alone. Most benign 
teratomas can be identified confidently based on imaging 
characteristics. In other cases, it is a combination of demo-
graphics, radiographic features, and the clinical setting that 
allows a presumptive diagnosis to be made with little doubt. 
In the patient with myasthenia gravis, pure red cell aplasia 
or hypogammaglobulinemia and an anterior mediastinal mass 
that has a typical CT appearance of thymoma, a biopsy is 
not needed to establish the diagnosis of a thymic malignancy. 
Recognition of these entities allows efficient progression to 
treatment (usually resection) without unnecessary and some-
times misleading extra steps.
In the case of anterior mediastinal lymphoma, while 
the diagnosis can often be established on clinical grounds, 
tissue is needed to fully characterize the tumor and define the 
optimal treatment. The diagnostic yield of transthoracic nee-
dle biopsy varies with the type of lymphoma and the biopsy 
type, which can lead to confusion about the success rate. For 
example, LB-NHL exhibits characteristic cytology and sim-
ple aspiration of fluid or bone marrow (involved in ~50%) is 
highly successful. Although a needle biopsy is highly diag-
nostic of lymphoma in general, the mediastinal lymphomas 
(HD/MLC-NHL) are dense and fibrotic making evaluation 
of such biopsies more difficult. Most reports of the success 
of needle biopsies involve either all lymphomas or include a 
large proportion where the issue was confirmation of recur-
rence, rather than initial subtyping. To sufficiently define 
specific characteristics of an anterior mediastinal lymphoma, 
multiple core needle specimens are typically needed (usually 
from 3 to 5) for architectural evaluation and immunohisto-
chemistry, as well as fine needle aspiration for flow cytom-
etry. However, the success rate of this combined core needle 
biopsy and aspiration approach of anterior mediastinal lym-
phoma is not well defined. Reports cite success rates varying 
from 13% to 92%, but often assess only one biopsy tech-
nique (fine needle aspiration or core biopsy) rather than the 
techniques combined, do not specify how many cores were 
obtained and include newly diagnosed as well as patients 
with recurrent disease.28–35 For example, in a 1991 study36 
evaluating core biopsy alone using light microscopy without 
immunohistochemical stains or flow cytometry, only 20% of 
FIGURE 3.  Anterior mediastinal tumors in children under 
age 10 years. Proportion of tumor types by years of age: 
Modified from Detterbeck.1
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15 patients with HD were diagnosed correctly; four patients 
with HD and one with non-HD were misdiagnosed as thy-
moma, whereas two patients with lymphocyte-rich thymoma 
were misdiagnosed as having lymphoma. A more thorough 
approach with multiple core biopsies in combination with 
flow cytometry yield better results and limit the number of 
patients who require a surgical biopsy. Nevertheless, skepti-
cism and pursuing larger tissue specimens is justified when 
there is a discrepancy between the clinical diagnosis and the 
biopsy results.
The approach outlined in this article leaves only a 
small proportion of patients in whom a presumptive clinical 
diagnosis cannot be reached and histology is necessary for 
diagnosis and/or treatment planning. In such situations, it is 
generally more useful to obtain tissue than to pursue other 
imaging tests (such as MRI or PET). Numerous techniques 
may be employed in the biopsy of an anterior mediastinal 
mass, the most common of which include CT-guided trans-
thoracic needle biopsy, video-assisted thoracoscopic surgery 
(VATS), mediastinotomy, and open surgical biopsy. Each of 
these methods has inherent strengths and weaknesses, and the 
selection of techniques depends on different lesion charac-
teristics such as size, location, and heterogeneity and patient 
characteristics such as age and comorbidities. Although min-
imally invasive techniques such as CT-guided transthoracic 
biopsy may be desirable to patients, more invasive proce-
dures may need to be performed to obtain adequate tissue. 
For instance, a survey of members of the European Society of 
Thoracic Surgeons revealed that most respondents preferred 
surgical biopsy by VATS or mediastinotomy to transthoracic 
needle biopsy.37 VATS excisional biopsies may be performed 
on small, encapsulated lesions without invasion of structures 
such as the phrenic nerve, major vascular structures, lung, or 
sternum. It should be noted that many surgeons recommend 
that VATS incisional biopsies not be performed in patients 
with possible thymic malignancies.
CONCLUSION
This article describes an approach to evaluation of 
patients with an anterior mediastinal mass. Readily avail-
able information (age and gender), combined with particu-
lar radiographic or clinical features that are often present 
allows identification of a presumptive clinical diagnosis 
with a high degree of confidence in most patients. This 
permits a more directed approach to obtaining further tests 
to confirm the presumptive diagnosis or more fully char-
acterize the lesion. Because the information often comes 
from different sources, good communication and collabor-
ative judgment between several specialties is tremendously 
helpful. This structured clinically oriented approach to 
patients with an anterior mediastinal mass narrows and 
focuses the diagnostic evaluation, eliminating unnecessary 
and sometimes misleading steps in the process.
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